M1 Kliniken AG

  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 12.07.2019 | 09:32

M1 Kliniken AG publishes 2018 consolidated financial statements and proposes dividend of 0.30 Euro per share

DGAP-News: M1 Kliniken AG / Key word(s): Annual Results/Dividend

12.07.2019 / 09:32
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG publishes 2018 consolidated financial statements and proposes dividend of 0.30 Euro per share

- Consolidated sales +38% to Euro 65.2 million

- Consolidated net income +14% to Euro 6.6 million

- Dividend proposal to the Annual General Meeting: EUR 0.30 per share

- Positive outlook: double-digit growth in sales and earnings in 2019


Berlin, 12.07.2019 - M1 Kliniken AG (ISIN: DE000A0STSQ8) today published its consolidated financial statements for 2018. The M1 Group further expanded its market leadership in Germany in the field of beauty medicine and expanded its range of services with "M1 Laser" and "M1 Dental" to include dermatological laser and aesthetic dental treatments. Despite the start-up costs of the numerous new locations, the training and further education of the now more than 60 doctors in the M1 Academy as well as investments in new fields of treatment and markets, the profit was again increased in 2018. Due to the pleasing result the growth company will propose the distribution of a dividend of EUR 0.30 per share to the Annual General Meeting. Based on yesterday's closing price of EUR 13, this results in a dividend yield of 2.3%.

The M1 Group increased consolidated sales by 38% to EUR 65.2 million in fiscal year 2018 (2017: EUR 47.2 million). Earnings before taxes rose from EUR 7.4 million to EUR 8.1 million. Consolidated net income increased by 14% to Euro 6.6 million (2017: EUR 5.8 million). Despite the capital increase in September 2018, M1 improved earnings per share to EUR 0.39 (2017: EUR 0.38). At over 90%, the equity ratio remains at a very high level. Despite the strong growth, the operating cash flow increased to EUR 2.8 million.

According to current planning, the Management Board expects the growth path to continue in 2019 and expects double-digit increases in Group sales and earnings. A major focus of M1's business activities in the current year will be the opening of further specialist centres in Germany and abroad. A significant expansion of international activities will take place in the UK, Austria, Switzerland and the Netherlands. M1 has already secured financing for its national and international expansion through a capital increase in September 2018. Furthermore, management and corporate governance structures are to be strengthened and adapted to the strong operational growth.

The Annual Report 2018 of M1 Kliniken AG for download: www.m1-kliniken.de

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, M1 Laser and M1 Dental, beauty medical treatments are currently offered at more than 25 locations. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe The Group is now also growing in other European countries and markets high-quality products to private customers, doctors, pharmacies and wholesalers under the "M1 Select" and "M1 Aesthetics" brands. www.m1-kliniken.de


M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: ir@m1-kliniken.de

12.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Anleihe im Fokus

Deutsche Rohstoff
"Anleihe - Jetzt zeichnen!"

- Emissionsvolumen: bis zu 100 Mio. EUR
- Zeichnungsfrist: 11.11. bis 04.12.2019
- ISIN: DE000A2YN3Q8 / WKN: A2YN3Q
- Börsenesegment: Börse Frankfurt, Open Market (Quotation Board)
- Stückelung / Emissionspreis: 1.000 EUR/ 100%
- Zinssatz (Kupon): 5,25 %
- Laufzeit: 5 Jahre
- Fälligkeit: 5 Jahre / 6.12.2024 (vorbehaltliche vorzeitige Rückzahlung gemäß Anleihebedingungen)
- Zinszahlung: Angebot an Inhaber der 5,625 % Schuldverschreibung 2016/2021 (WKN A2AA05, ISIN DE000A2AA055) diese in die neue Anleihe zu tauschen
- Umtauschfrist: 11.11.2019 – 29.11.2019 (18.00 Uhr)


Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

Aktueller Webcast

EQS Group AG

Conference Call zu den Neunmonatszahlen 2019

15. November 2019

Aktuelle Research-Studie

Media and Games Invest plc

Original-Research: Media and Games Invest plc (von GBC AG): Kaufen

18. November 2019